Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate

Hepatology. 2021 Jun;73(6):2598-2600. doi: 10.1002/hep.31613. Epub 2021 May 25.

Authors

Lena Smets¹, Jef Verbeek^{1

2}, Hannelie Korf¹, Schalk van der Merwe^{1

2}, Frederik Nevens^{1

2}

Affiliations

¹ Laboratory of Hepatology, CHROMETA Department, KU Leuven, Leuven, Belgium.
² Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium is part of the Members of the European Reference Networks RARE-LIVER.

PMID: 33140868
DOI: 10.1002/hep.31613

No abstract available

MeSH terms

Alkaline Phosphatase / blood
Bezafibrate* / administration & dosage
Bezafibrate* / adverse effects
Bilirubin / blood
Chenodeoxycholic Acid / administration & dosage
Chenodeoxycholic Acid / adverse effects
Chenodeoxycholic Acid / analogs & derivatives*
Cholestasis* / diagnosis
Cholestasis* / drug therapy
Cholestasis* / etiology
Cholestasis* / physiopathology
Cholesterol / blood
Dose-Response Relationship, Drug
Drug Interactions
Drug Monitoring / methods
Female
Humans
Hypolipidemic Agents / administration & dosage
Hypolipidemic Agents / adverse effects
Liver Cirrhosis, Biliary* / blood
Liver Cirrhosis, Biliary* / complications
Liver Cirrhosis, Biliary* / therapy
Liver Function Tests / methods
Male
Middle Aged
Pruritus* / chemically induced
Pruritus* / prevention & control
Treatment Outcome

Substances

Hypolipidemic Agents
obeticholic acid
Chenodeoxycholic Acid
Cholesterol
Alkaline Phosphatase
Bilirubin
Bezafibrate